PRCT vs TFX
PRCT: PROCEPT BioRobotics provides an advanced, heat-free robotic surgical solution for the treatment of benign prostatic hyperplasia (BPH) through its proprietary Aquablation therapy. TFX: Teleflex is a medical technology company specializing in single-use devices for critical care and surgical applications, currently streamlining its portfolio to focus on core operations.
Side-by-side fundamentals
| Metric | PRCT | TFX | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $17.70 | $134.80 | |
| Market cap as of 2026-07-23 | $1.0B | $6.0B | |
| PEG as of 2026-07-23 | -1.33 | 0.73 | PRCT lower |
| Net margin as of 2026-07-23 | -31.8% | -35.9% | PRCT higher |
| Gross margin as of 2026-07-23 | +64.0% | +53.3% | PRCT higher |
| Operating margin as of 2026-07-23 | -33.9% | -7.8% | TFX higher |
| ROE as of 2026-07-23 | -27.7% | -28.3% | PRCT higher |
| ROA as of 2026-07-23 | -20.3% | -13.9% | TFX higher |
| Debt / equity as of 2026-07-23 | 0.15 | 0.85 | PRCT lower |
| Revenue growth (YoY) as of 2026-07-23 | +29.3% | -6.6% | PRCT higher |
| Revenue CAGR (3y) SEC XBRL | +60.1% | -10.6% | PRCT higher |
| Dividend yield as of 2026-07-23 | n/a | +1.0% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-23 | 0.92 | 0.81 | |
| 1-year return as of 2026-07-22 close | -69.9% | +17.0% | TFX higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.